Afficher la notice abrégée

Risk of skin ulcer and use of COX-2 inhibitors: A national population-based nested case control study

dc.rights.licenseopenen_US
dc.contributor.authorPEREZ, J.
dc.contributor.authorROUSTIT, Matthieu
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBEZIN, Julien
dc.contributor.authorBLAISE, Sophie
dc.contributor.authorCRACOWSKI, Jean-Luc
dc.contributor.authorKHOURI, Charles
dc.date.accessioned2022-07-15T13:52:57Z
dc.date.available2022-07-15T13:52:57Z
dc.date.issued2022-06
dc.date.conference2022-06-14
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/140507
dc.descriptionMeeting abstracten_US
dc.description.abstractEnIntroduction: Cardiovascular adverse effects of COX-2 inhibitors are well described. Nevertheless, no study explored the cutaneous and vascular adverse effects of COX-2 inhibitors [1]. The aim of this study is to identify and quantify the risk of skin ulcer associated with COX-2 inhibitors in real world setting. Material and methods: A population-based nested case control study was conducted from a representative sample of the French nationwide claims database, “EGB,” for the 2012–2016 period [2]. Cases were defined as patients who had consumed at least two boxes of wound dressing during 1 month between 2012 and 2016. The index date was the date of first period of reimbursement of wound dressing for skin ulcer. Up to four potential controls were selected for each case among subjects free from skin ulcers. Conditional logistic models were used to estimate adjusted odds ratios (aORs) and their 95% CIs. Cumulative exposure of drug class was considered using quartile as a categorical variable. The status of exposure was defined using a categorical variable. Results: For diabetes foot ulcers, pressure ulcers, and vascular ulcers, respectively 19,982, 4,584, and 41,632 cases fulfilled the inclusion criteria. Among cases and controls, an increased risk of all types of ulcers was found for a cumulative exposure to COX-2 inhibitors exceeding 90 days with aOR = 1.35 (95% CI 1.03–1.77) for diabetic foot ulcer, aOR = 2.04 (95% CI 1.63–2.56) for pressure ulcers, and aOR = 1.89 (95% CI 1.71–2.11) for vascular ulcers. Current exposure was associated with a higher risk of skin ulcer with aOR = 1.63 (95% CI 1.06–2.49) for diabetic foot ulcer, aOR = 2.20 (95% CI 1.52–3.19) for pressure ulcers, and aOR = 3.0 (95% CI 2.57–3.52) for vascular ulcers. Discussion/Conclusion: Our results suggest that COX-2 inhibitors are associated with a dose and time-dependent risk of skin ulcers. Given the observational nature of this study, we cannot exclude unmeasured and residual confounding.
dc.language.isoENen_US
dc.title.enRisk of skin ulcer and use of COX-2 inhibitors: A national population-based nested case control study
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/fcp.12788
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
bordeaux.journalFundamental and Clinical Pharmacology
bordeaux.page87-88en_US
bordeaux.volume36en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.conference.titleAnnual Meeting of French Society of Pharmacology and Therapeuticsen_US
bordeaux.countryfren_US
bordeaux.teamAHEAD_BPHen_US
bordeaux.conference.cityLilleen_US
bordeaux.peerReviewedouien_US
hal.identifierhal-03724902
hal.version1
hal.date.transferred2022-07-15T21:24:58Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Fundamental%20and%20Clinical%20Pharmacology&rft.date=2022-06&rft.volume=36&rft.spage=87-88&rft.epage=87-88&rft.au=PEREZ,%20J.&ROUSTIT,%20Matthieu&BEZIN,%20Julien&BLAISE,%20Sophie&CRACOWSKI,%20Jean-Luc&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée